Human papillomavirus type 16 E7-derived peptide epitope (HPV16 E7 epitope)

Human papillomavirus type 16 (HPV16) E7-derived peptide epitopes are specific immunogenic fragments of the E7 oncoprotein, which is a critical driver of HPV-associated malignancies including cervical, oropharyngeal, and anogenital cancers (NCI Drug Dictionary, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/human-papillomavirus-16-e7-peptide). These epitopes are processed by the cellular proteasome and presented on the cell surface via Major Histocompatibility Complex (MHC) molecules, such as HLA-A*02:01, where they are recognized by the T-cell receptors (TCRs) of cytotoxic T-lymphocytes (Frontiers in Immunology, 2020, https://doi.org/10.3389/fimmu.2020.01442). Because the E7 protein is essential for maintaining the malignant phenotype by inactivating the retinoblastoma (Rb) tumor suppressor, these epitopes serve as stable and specific targets for therapeutic intervention. Current therapeutic strategies include peptide-based vaccines (e.g., ISA101), DNA vaccines (e.g., VGX-3100), and TCR-engineered T-cell therapies (e.g., KITE-439) designed to elicit a robust immune response against HPV-infected cells (NIH, 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601141/). Unlike prophylactic vaccines that target the viral capsid to prevent infection, E7-targeted therapies aim to eliminate established tumors by inducing the immune-mediated destruction of malignant cells (Cancer Biology & Medicine, 2025, https://doi.org/10.20892/j.issn.2095-3941.2024.0345). Therapeutic success depends on the stable presentation of these epitopes and the ability of the immune system to overcome the immunosuppressive tumor microenvironment.

Other names

HPV16 E7 antigenHPV16 E7 peptideE7 11-19 epitopeE7 49-57 epitopeE7 82-90 epitopeHPV16 E7 CTL epitopeHuman papillomavirus type 16 E7 peptideHPV16 E7-derived T-cell epitope

Drugs targeting HPV16 E7-derived peptide epitopes work by inducing or providing a cellular immune response. Therapeutic vaccines (peptide, DNA, or viral vector-based) deliver the epitope to antigen-presenting cells, which then present the peptide-MHC complex to naive T cells, stimulating the expansion of antigen-specific cytotoxic T-lymphocytes (CTLs). Adoptive cell therapies, such as TCR-T cells, involve the infusion of T cells engineered with a T-cell receptor specifically designed to recognize the E7 peptide-MHC complex on the surface of tumor cells. Upon recognition, these T cells release perforins and granzymes to induce apoptosis in the target HPV-positive malignant cells (NIH, 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601141/; Frontiers in Immunology, 2020, https://doi.org/10.3389/fimmu.2020.01442).